News

Reverdia and Helm join forces
Enlarge image

BusinessNetherlandsFranceGermany

Reverdia and Helm join forces

18.10.2012 - Reverdia and Helm have partnered to market the bioplastics compound succinic acid on industrial scale.

Reverdia, the joint venture from Dutch DSM and French Roquette, has joined forces with Hamburg-based Helm AG for production and marketing in the highly competitive European market for bio-based succinic acid. The chemical building block for bioplastics, organic solvents and elastic fibres, is predicted to reach sales of 4-7bn annually in the mid-term.

„Reverdia’s Biosuccinium does not only offer an alternative to petrochemical succinic acid, but also for other fossil-based acids like adipic acid, so the market potential is huge”, stressed Christina Wienholz, Senior Executive Manager at Helm, who will take the part of marketing. “Our partnership with Helm will deliver expanded market development capacity for Reverdia in Europe“, said Reverdia chief Jo Kockelkoren, whose company has set up a plant-derived sugar fermentation process in yeast. His company aims at becoming the first company in the world to produce succinic acid on commercially large scale. Reverdia plans to complete a production plant with an annual capacity of 10,000 metric tons in Cassano Spinola, Italy, at the end of this year.

The move came just a week after German chemical major BASF and its Dutch partner Purac N.V. announced a joint-venture named Succinity to produce and market succinic acid. The companies want to start production after reconstruction of a 10,000 ton plant near Barcelona is finished in late 2013. US firm Myriant Inc. has also announced completion of construction of a 13,000 ton bio-succinic acid production plant in Quincy, Massachusetts, for the end of 2012. Bioamber Inc. is already marketing the bio-based compound since 2011, which is produced from E. coli in its Pomacle plant (France) that has an annual capacity of 2,000 metric tons. Succinity, however, may have a competitive edge because its process can also use glycerol, a byproduct of biodiesel production, as a feedstock.

According to the companies, biosuccinic acid could be used to produce coolants, surfactants, adhesives, corrosion inhibitors, lubricants, photo development fluids, herbicides, soldering pastes, runway deicers, polyurethanes, coating resins, phthalate-free plasticizers, polybutylene succinate (PBS) and many others.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/reverdia-and-helm-join-forces.html

Stock marketsEU

29.01.2015 Denmark's Ascendis Pharma has successfully raised US$108m with its upsized NASDAQ IPO, while Irish animal health specialist Nexvet is waiting in the wings.

Contract ResearchEU

28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

M&ASwitzerlandFrance

09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CO.DON2.40 EUR11.63%
  • SARTORIUS113.95 EUR4.93%
  • EVONIK27.85 EUR3.69%

FLOP

  • ADDEX3.30 CHF-4.07%
  • BIOFRONTERA1.95 EUR-3.47%
  • MEDIGENE3.70 EUR-2.63%

TOP

  • CYTOS0.33 CHF43.5%
  • ADDEX3.30 CHF42.2%
  • FORMYCON14.30 EUR41.9%

FLOP

  • BIOFRONTERA1.95 EUR-15.2%
  • ACTELION100.20 CHF-13.8%
  • MOLOGEN5.60 EUR-11.8%

TOP

  • SANTHERA105.50 CHF2570.9%
  • WILEX1.96 EUR168.5%
  • BB BIOTECH256.75 EUR98.6%

FLOP

  • CYTOS0.33 CHF-90.9%
  • MOLOGEN5.60 EUR-51.0%
  • 4SC0.82 EUR-50.9%

No liability assumed, Date: 29.01.2015